- Details
- Sam Chang hosts a discussion with Gal Wald and Eugene Pietzak about intravesical gemcitabine and BCG combination therapy for BCG-exposed non-muscle-invasive bladder cancer. The phase II trial demonstrates promising results with a 94% complete response rate at six months and 81% at twelve months using an alternating schedule of gemcitabine and BCG over ten weeks. The treatment shows a favorable tox...
|
- Details
- Cheryl Lee joins Zachary Klaassen to discuss the top 10 reasons why BCG as monotherapy for bladder cancer will likely cease to exist. She outlines various challenges with BCG therapy, including administration difficulties, treatment intensity, and worldwide shortages, while highlighting emerging alternatives and novel therapeutic approaches. Dr. Lee emphasizes the promise of targeted agents, impro...
|
- Details
- Zachary Klaassen and Joshua Meeks discuss the need to move beyond single-arm trials in BCG-unresponsive bladder cancer treatment, given the current availability of multiple FDA-approved options. Dr. Meeks advocates for transitioning to randomized controlled trials to enable direct comparisons between treatments, suggesting a model similar to the STAMPEDE trial in prostate cancer. He proposes stand...
|
- Details
- Zachary Klaassen and Sia Daneshmand discuss the SunRISe-1 trial results examining TAR-200, a novel device that provides sustained release of gemcitabine in the bladder for BCG-unresponsive non-muscle invasive bladder cancer. The Phase IIb study demonstrates an impressive 83.5% complete response rate with the device, which remains in place for three weeks at a time. Dr. Daneshmand highlights the fa...
|
- Details
- Zachary Klaassen and Amanda Myers discuss a single-institution study examining response rates to additional BCG therapy in high-risk non-muscle invasive bladder cancer patients. Dr. Myers presents data analyzing outcomes in both BCG-exposed and BCG-unresponsive populations, providing benchmark response rates to inform clinical trial design. The study demonstrates high success rates with additional...
|
- Details
- Zachary Klaassen and Trinity Bivalacqua discuss Cohort B of the CORE-008 trial, which examines cretostimogene in BCG-exposed patients with high-risk non-muscle invasive bladder cancer. The phase 2 multi-cohort, multicenter study focuses on patients who have recurrent high-grade disease but do not meet BCG-unresponsive criteria. The treatment protocol includes a six-week induction course of cretost...
|
- Details
- Trinity Bivalacqua joins Zachary Klaasen to discuss the CORE-008 trial, specifically focusing on cohort A, which examines cretostimogene in high-risk, non-muscle-invasive bladder cancer. The conversation explores this phase II multi-cohort, multicenter, open-label study that targets BCG-naive patients with CIS, with or without papillary disease. The treatment protocol involves a six-week induction...
|
- Details
- Zachary Klaassen and Amanda Myers discuss a US claims analysis examining real-world treatment patterns following BCG induction in non-muscle invasive bladder cancer patients. The study reveals significant underutilization of maintenance BCG therapy, with only a quarter of patients receiving adequate maintenance doses after induction. Their analysis highlights considerable heterogeneity in subseque...
|
- Details
- Tracey Krupski explores the implementation of tele-cystoscopy to improve access to bladder cancer care in resource-challenged areas. Dr. Krupski shares research demonstrating how trained advanced practice providers can perform remote cystoscopies while urologists supervise via video connection, significantly reducing travel burden for patients in underserved regions. The study validates the approa...
|
- Details
- Sam Chang hosts Eugene Pietzak to discuss treatment options for BCG-unresponsive bladder cancer and the challenges of evaluating their comparative effectiveness. Dr. Pietzak emphasizes that while multiple FDA-approved treatments are now available, including pembrolizumab, nadofaragene, and BCG with IL-15 superagonist, comparing their efficacy is complicated by variations in trial designs, surgeon...
|
